Se connecter

Bibliographies thématiques / Antibodies, Monoclonal

Sommaire

Articles de revues
Thèses
Livres
Chapitres de livres
Actes de conférences
Rapports d'organisations

Littérature scientifique sur le sujet « Antibodies, Monoclonal »

Auteur : Grafiati

Publié le 4 juin 2021

Mis à jour le 31 janvier 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Antibodies, Monoclonal ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Antibodies, Monoclonal"

1

Rieger, Paula Trahan. « Monoclonal Antibodies ». American Journal of Nursing 87, n^o 4 (avril 1987) : 469. http://dx.doi.org/10.2307/3470440.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Kosmas, C., H. Kalofonos et A. A. Epenetos. « Monoclonal Antibodies ». Drugs 38, n^o 5 (novembre 1989) : 645–57. http://dx.doi.org/10.2165/00003495-198938050-00001.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

&NA;. « Monoclonal antibodies ». Reactions Weekly &NA;, n^o 1293 (mars 2010) : 36. http://dx.doi.org/10.2165/00128415-201012930-00100.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

&NA;. « Monoclonal Antibodies ». Journal of Pediatric Hematology/Oncology 25, n^o 4 (avril 2003) : S5—S6. http://dx.doi.org/10.1097/00043426-200304000-00025.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

&NA;. « Monoclonal Antibodies ». Journal of Pediatric Hematology/Oncology 25, n^o 4 (avril 2003) : S17—S18. http://dx.doi.org/10.1097/00043426-200304000-00036.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Anderson, Philip O. « Monoclonal Antibodies ». Breastfeeding Medicine 11, n^o 3 (avril 2016) : 100–101. http://dx.doi.org/10.1089/bfm.2016.0026.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Nowak, Thomas P. « Monoclonal Antibodies ». American Journal of Clinical Oncology 10, n^o 4 (août 1987) : 278–80. http://dx.doi.org/10.1097/00000421-198708000-00002.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Ghobrial, Rafik M., Ronald W. Busuttil et Jerzy W. Kupiec-Weglinski. « Monoclonal antibodies ». Current Opinion in Organ Transplantation 2, n^o 1 (octobre 1997) : 82–88. http://dx.doi.org/10.1097/00075200-199710000-00015.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Rosen, Steven T., Elyse A. Lambiase, Yixing Ma, James A. Radosevich et Alan L. Epstein. « Monoclonal antibodies ». Postgraduate Medicine 77, n^o 4 (mars 1985) : 129–34. http://dx.doi.org/10.1080/00325481.1985.11698922.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Rabin, Brace S. « Monoclonal antibodies ». Postgraduate Medicine 79, n^o 1 (janvier 1986) : 293–303. http://dx.doi.org/10.1080/00325481.1986.11699254.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "Antibodies, Monoclonal"

1

Austin, Eric B. « Human monoclonal antibodies ». Thesis, University of Nottingham, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.276187.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Plumpton, Christopher. « Monoclonal antibodies against phytochrome ». Thesis, University of Cambridge, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.358677.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Benjamin, Richard John. « Tolerance induction with monoclonal antibodies ». Thesis, University of Cambridge, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.253988.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Qin, Shi-Xin. « Transplantation tolerance with monoclonal antibodies ». Thesis, University of Cambridge, 1989. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.305697.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Heron, Andrew David. « The stability of monoclonal antibodies ». Thesis, University of Glasgow, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.252169.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Isaacs, John Dudley. « Improving serotherapy with monoclonal antibodies ». Thesis, University of Cambridge, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.386115.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Paudel, Subhash. « Shear thinning in monoclonal antibodies ». Thesis, Kansas State University, 2016. http://hdl.handle.net/2097/32833.

Texte intégral

Résumé :

Master of Science
Department of Physics
Jeremy D. Schmit
Antibodies are large Y-shaped proteins which are used by immune system to identify and neutralize pathogens. Monoclonal antibody therapy is used to treat different patient conditions. There are problems associated with the manufacturability and deliverability of mAb solutions due to the viscous nature of the protein. The viscosity of antibody solutions increases with the increase in concentration and decreases with applied shear. We want to know why these behaviours are seen and to address this problem we have developed a theory describing the rapid viscosity increase with increasing concentration. We use the polymer theory to explain this behaviour. Here antibodies are treated as polymers. The length of the polymer depend on the aggregation. The reptation time increases approximately as the cubic power of size of aggregate (N³ ). We see the shear thinning behaviour is dependent on the Ab-Ab binding energy and find the relationship between the size of the aggregate and the binding energy. We find aggregate size and morphology using several models for Ab-Ab interaction sites. We use the head to head binding (fAb-fAb binding) model to describe aggregation state in our viscosity theory. The size of the aggregate and hence the reptation time is captured by the binding energy. When the binding energy increases the zero shear viscosity increases and the reptation time decreases. Likewise when the binding energy decreases the zero shear viscosity decreases and the reptation time increases. We have yet to find the correct exponents for the shear thinning behaviour of different mAbs which would be our future work.

Styles APA, Harvard, Vancouver, ISO, etc.

8

Ueda, Yasuji. « MONOCLONAL ANTIBODIES TO CHICK CRYSTALLINS ». 京都大学 (Kyoto University), 1989. http://hdl.handle.net/2433/86412.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Alexandrovich, Susan K. « Characterization of monoclonal antibodies against digoxin / ». Online version of thesis, 1987. http://hdl.handle.net/1850/10681.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Mirza, Myriam. « Characterization of new CFTR monoclonal antibodies ». Thesis, McGill University, 2009. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=66882.

Texte intégral

Résumé :

The available antibodies against CFTR are not sensitive enough to detect CFTR at endogenous or near endogenous levels making detection at native levels difficult. We raised two monoclonal antibodies, 22E8 and 23C5, against the R domain of human CFTR with the goal of identifying an antibody sensitive enough to detect CFTR in native airway cells. These antibodies were characterized for their ability to detect over-expressed as well as endogenous levels of CFTR in immunoblotting, immunoprecipitation and immunofluorescence. Their ability to detect CFTR was also compared with commercial antibodies M3A7 and 24-1. We show that 23C5 and 22E8 are more sensitive than the commercial antibodies and are able to detect CFTR in over-expressed and endogenous cells by immunoblotting. However, only 23C5 is able to immunoprecipitate CFTR and neither is able to detect CFTR in native airway cells by immunoblotting or are suitable for immunofluorescence. These antibodies will enable studies of CFTR biogenesis in endogenous cells.
A l'heure actuelle les anticorps dirigés contre la protéine CFTR ne sont pas suffisamment sensibles pour détecter cette protéine de facon endogène rendant ainsi l'étude de cette protéine difficile dans les tissus. Notre laboratoire a fabriqué deux anticorps monoclonaux , nommés 22E8 et 23C5, dirigés contre le domaine R de la protéine CFTR. L'abilité de ces anticorps à détecter l'expression de CFTR que ce soit de façon endogène ou lorsque la protéine est surexprimée a été testée à l'aide des techniques d'immunoblotting, d'immunoprécipitation et d'immunofluorescence. Afin de verifier leur sensibilité et leur capacité à détecter la protéine CFTR, ces anticorps ont été comparés aux anticorps M3A7 et 24-1 qui sont disponibles dans le commerce et connus pour détecter de facon optimale la protéine CFTR. Les resultats obtenus dans les lignées cellulaires à l'aide de la technique d'immunoblotting ont permis de montrer que les anticorps 23C5 et 22E8 sont plus sensibles que les anticorps commerciaux, de plus ils sont capables de détecter à la fois les protéines endogènes et sur-exprimées. Bien que l'anticorps 23C5 soit capable d'immunoprécipiter la protéine CFTR, aucun des deux anticorps n'a permis la detection de la protéine CFTR par immunoblotting dans les cellules de culture primaire. De plus, ces anticorps n'ont pas permis la detection de la protéine CFTR par immunofluorescence. Ainsi l'utilisation de ces anticorps nous donnera l'opportunité d'étudier la protéine CFTR dans les cellules l'exprimant de facon endogène afin de mieux comprendre sa regulation et son traffic.

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Livres sur le sujet "Antibodies, Monoclonal"

1

L, Beverley Peter C., dir. Monoclonal antibodies. Edinburgh : Churchill Livingstone, 1986.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Ossipow, Vincent, et Nicolas Fischer, dir. Monoclonal Antibodies. Totowa, NJ : Humana Press, 2014. http://dx.doi.org/10.1007/978-1-62703-992-5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Albitar, Maher, dir. Monoclonal Antibodies. Totowa, NJ : Humana Press, 2007. http://dx.doi.org/10.1007/978-1-59745-323-3.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Peters, Johann Hinrich, et Horst Baumgarten, dir. Monoclonal Antibodies. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Borrebaeck, Carl A. K., et James W. Larrick, dir. Therapeutic Monoclonal Antibodies. London : Palgrave Macmillan UK, 1990. http://dx.doi.org/10.1007/978-1-349-11894-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Steinitz, Michael, dir. Human Monoclonal Antibodies. Totowa, NJ : Humana Press, 2014. http://dx.doi.org/10.1007/978-1-62703-586-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

An, Zhiqiang, dir. Therapeutic Monoclonal Antibodies. Hoboken, NJ, USA : John Wiley & Sons, Inc., 2009. http://dx.doi.org/10.1002/9780470485408.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Steinitz, Michael, dir. Human Monoclonal Antibodies. New York, NY : Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4939-8958-4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

L, Macario Alberto J., et Conway de Macario Everly, dir. Monoclonal antibodies against bacteria. Orlando : Academic Press, 1985.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

A, Simmons Marie, dir. Monoclonal antibodies : New research. New York : Nova Biomedical Books, 2004.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Chapitres de livres sur le sujet "Antibodies, Monoclonal"

1

Peters, J. H., et D. Baron. « Introduction ». Dans Monoclonal Antibodies, 1–17. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4_1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Peters, J. H., M. Schulze, M. Grol, S. Schiefer, H. Baumgarten, J. Endl, H. Xu et al. « Demonstration of Monoclonal Antibodies ». Dans Monoclonal Antibodies, 316–461. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4_10.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Baron, D. « Safety Precautions at Work ». Dans Monoclonal Antibodies, 463–65. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4_11.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Peters, Johann Hinrich, et Horst Baumgarten. « Appendix ». Dans Monoclonal Antibodies, 466–74. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4_12.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Wiggenhauser, A., J. H. Peters et H. Baumgarten. « Preconditions for Hybridoma Technology ». Dans Monoclonal Antibodies, 18–38. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4_2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Baumgarten, H., M. Schulze, J. H. Peters et T. Hebell. « Immunization ». Dans Monoclonal Antibodies, 39–70. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4_3.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Wiggenhauser, A., J. H. Peters, H. Baumgarten et A. Borgya. « Taking Blood and Isolating Cells ». Dans Monoclonal Antibodies, 71–87. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4_4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Peters, J. H., E. Debus, H. Baumgarten, R. Würzner, M. Schulze et Helga Gerlach. « Cell Culture ». Dans Monoclonal Antibodies, 88–136. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4_5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Baron, D., J. H. Peters, R. K. H. Gieseler, S. Lenzner, H. Baumgarten, R. Würzner, B. Goller et Th Werfel. « Production of Hybridomas ». Dans Monoclonal Antibodies, 137–222. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4_6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Baumgarten, H., R. Franze, J. H. Peters, A. Borgya, D. Baron, E. Debus et M. Kubbies. « Mass Production of Monoclonal Antibodies ». Dans Monoclonal Antibodies, 223–57. Berlin, Heidelberg : Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-74532-4_7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Antibodies, Monoclonal"

1

Kiefel, V., S. Santoso et C. Mueller-Eckhardt. « ANALYSIS OF PLATELET REACTIVE ANTIBODIES USING MONOCLONAL ANTIBODIES ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643929.

Texte intégral

Résumé :

The characterization of platelet reactive alloantibodies and autoantibodies is mandatory for the diagnosis of posttransfusion purpura, neonatal alloimmune thrombocytopenia, autoimmune thrombocytopenia and for the selection of platelet donors prior to platelet transfusions in immunized polytransfused patients. The platelet immunofluorescence test is suitable for the detection of platelet reactive antibodies. In many cases, however, mixtures containing different platelet reactive antibodies have to be dissected.In order to analyze these sera, we have developed a novel enzyme immunoassay based upon monoclonal antibody specific immobilization of platelet antigens (MAIPA). In brief, platelets are incubated simultaneously with the (human) serum to be investigated and a monoclonal (mouse) antibody directed against an epitope on the same platelet membrane glycoprotein (GP). Platelets are then washed and solubilized in TRIS buffered saline containing NP40. The lysed platelets are then pipetted into the wells of microtiter plates, coated with goat anti mouse IgG where mouse anti GP-complexes are immobilized. Human platelet reactive antibodies on the same GP are detected using enzyme labelled goat anti human IgG, IgM, or IgA, respectively. Using mab Gi5, mab FMC25, mab w6.32 directed against epitopes on the glycoprotein complex IIb/IIIa, glycoprotein Ib and HLA class I molecule, respectively, and a panel of typed platelet donors, even sera containing different platelet reactive antibodies are readily analyzed. Results of experiments with platelet specific alloantibodies (anti P1A1, anti P1A2 and anti Bak(a)), autoantibodies (against the GP Ilb/IIIa complex and GP Ib) and a drug dependent antibody show that this assay allows to discriminate all these different platelet reactive antibodies.

Styles APA, Harvard, Vancouver, ISO, etc.

2

Yang, Wu, Li-ming Wang, Zhao Wei et Yuan Junlin. « Preliminary Production of Anti- Glufosinate Monoclonal Antibodies ». Dans 2007 1st International Conference on Bioinformatics and Biomedical Engineering. IEEE, 2007. http://dx.doi.org/10.1109/icbbe.2007.18.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Young, Colin R., Alice Lee et Larry H. Stanker. « Detection of Campylobacter species using monoclonal antibodies ». Dans Photonics East (ISAM, VVDC, IEMB), sous la direction de Yud-Ren Chen. SPIE, 1999. http://dx.doi.org/10.1117/12.335779.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Ray, Jason C., Penelope Allen, Ann Bacsi, Julian Bosco, Luke Chen, Michael Eller, Lyndell Lim et al. « 076 Inflammatory complications of CGRP monoclonal antibodies ». Dans ANZAN Annual Scientific Meeting 2021 Abstracts. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/bmjno-2021-anzan.76.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Metzelaar, M. J., H. K. Nieuwenhuis et J. J. Sixma. « DETECTION OF ACTIVATED PLATELETS WITH MONOCLONAL ANTIBODIES ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643829.

Texte intégral

Résumé :

Blood tests reflecting in-vivo activation of platelets are potentially useful in evaluating patients with thrombotic diseases. Recently monoclonal antibodies have been described that react preferentially with activated platelets. We prepared an IgG2b antibody, designated RUU-AP 2.28, that reacted with a 53.000 MW protein that is located in a special subclass of platelet granules in unstimulated platelets and that is exposed on the surface of activated platelets. Increased numbers of platelets that expressed the 2.28 antigen on their surface were observed in patients undergoing cardiopulmonary bypass and in patients with acute deep venous thrombosis. The percentage of RUU-AP 2.28 positive platelets in the circulation was 3,9 ± 2.7 (SD)% in the controls, (n = 20), 24.6 ± 13.5% in patients after cardiopulmonary surgery (n = 10) and 8.5% in patients with acute deep venous thrombosis (n = 2).In order to detect also earlier stages of platelet activation, such as secretion-independent phenomena, we produced new monoclonal antibodies by fusing spleen cells from Balb/c mice, immunized with thrombin stimulated, paraformaldehyde fixed platelets, with Ag 8653 myeloma cells. As a screening assay we used an ELISA with freshly fixed platelets or fixed thrombin-activated platelets. We detected six monoclonal antibodies (RUU-AP 1-6) specific for thrombin-activated platelets. The results of the ELISA were confirmed by flow cytofluorometry.None of the antibodies inhibited platelet aggregation induced by ADP, collagen or ristocetin. Ascites of IgGl antibody RUU-AP 3 reacted with normal thrombin-activated platelets but did not react with thrombin-activated platelets from a patient with Glanzmann’s disease. In addition antibody RUU-AP 3 reacted with normal platelets stimulated with 1 pM of ADP. These data suggest that antibody RUU-AP 3 detects a secretion-independent conformational change in the platelet membrane glycoprotein IIb-IIIa complex.

Styles APA, Harvard, Vancouver, ISO, etc.

6

Brown, Michael C., Ross Chambers, Dale V. Onisk, Tony R. Joaquim, Lewis J. Stafford, Klaus Lindpaintner, Daniel Keter et James W. Stave. « Abstract 4325 : Monoclonal antibodies to transmembrane proteins. » Dans Proceedings : AACR 104th Annual Meeting 2013 ; Apr 6-10, 2013 ; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4325.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Hessing, Martin, Joost C. M. Meijers, Jan A. van Mourik et Bonno N. Bouma. « MONOCLONAL ANTIBODIES TO HUMAN PROTEIN S AND C4b-BINDING PROTEIN ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644291.

Texte intégral

Résumé :

Protein S (PS) circulates in plasma both free and in reversible association with the complement component C4b-binding protein (C4bp). Only free PS is functional as a cofactor for activated protein C (APC). Cleavage of PS by thrombin at a site near the r-carboxyglutamic acid domain is associated with a loss of cofactor activity. This may be a control mechanism for the anticoagulant activity of APC. These observations led us to investigate the role of C4bp and thrombin in the regulation of PS. Complex formation between purified PS and C4bp was studied in plasma and in a system with purified components. 125I-labeled PS was first incubated with either C4bp or citrated plasma and then subjected to polyacrylamide gelelectrophoresis in the absence of SDS. The formation of the C4bp-PS complex in plasma and in the purified system was demonstrated by autoradiography. Crossed immuno-electrophoresis using an antiserum against PS was performed in the presence of 8 mM EDTA. Human citrated plasma showed two precipitin peaks. Free PS migrated rapidly in the first dimension, whereas the C4bp-PS complex was just anodal to the application slot. The addition of C4bp to either plasma or purified PS resulted in the disappearance of the free PS peak and an increase of the slower migrating peak. The effect of purified C4bp on the PS-cofactor function of APC was studied in citrated plasma. The prolongation of the APTT induced by the addition of APC could be inhibited by the addition of increasing amounts of C4bp. Monoclonal antibodies to PS and C4bp were prepared and characterized. The monoclonal antibodies to either PS or C4bp did not block the complex formation between and PS, as was demonstrated by dot blotting of C4bp with 125I-PS and agarose gelelectrophoresis followed by Western blotting. Three out of 7 monoclonal antibodies to PS did not detect PS after thrombin cleavage on an immunoblot after non-reduced SDS polyacrylamide gelelectrophoresis. These 3 antibodies gave a significant shortening of the prolonged APTT induced by the addition of APC to normal plasma, indicating that these monoclonals inhibited the cofactor function of PS. The other 4 monoclonals to PS that did detect PS after thrombin cleavage on an immunoblot, gave only a minor inhibition of the PS cofactor function.

Styles APA, Harvard, Vancouver, ISO, etc.

8

Clemetson, K. J., R. Weber et J. L. McGregor. « TOPOLOGY OF PLATELET GPIb INVESTIGATED BY LOCATION OF MONOCLONAL ANTIBODY EPITOPES ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643625.

Texte intégral

Résumé :

A large number of monoclonal antibodies to platelet membrane glycoprotein lb (GPIb) have been described but for most of these the position of the epitope is not known. Since many of these influence platelet function, a better understanding of struc-ture-function relationships requires this knowledge. The position of the epitopes for the monoclonal antibodies API (Dr. T.J. Kunicki), AN51 and SZ-2 (Dr. C-G. Ruan), WM23 (Dr. M.C. Berndt) and PI were determined by analysis of proteolytic cleavage fragments of glycocalicin via affinity chromatography on the monoclonal antibodies coupled to Sepharose, elution with diethyl ami ne solution, separation on SDS-gel electrophoresis and detection by silver-staining. First, intact glycocalicin was examined and was found to bind to all monoclonals with the exception of PI. All monoclonals bound intact GPIb. WM23 bound a 70 kDa glycopeptide from the highly-glycosylated 90 kDa tryptic fragment of glycocalicin. API, AN51 and SZ-2 all bound to 45 kDa and 40 kDa, poorly glycosylated tryptic fragments. The 40 kDa fragment is derived from the 45 kDa fragment and has been shown to be the N-terminal region of GPIb. All these monoclonals have been shown to inhibit von Willebrand factor induced platelet agglutination. Platelets were treated with either elastase or calcium activated protease and monoclonal binding checked by immunofluorescence. The immunofluorescence with API, AN51 and SZ-2 was minimal compared to control platelets whereas that of PI remained as strong as the controls. This indicates that the epitope for PI lies on GPIb in a region other than glycocalicin and its absence from glycocalicin is not simply due to conformational changes in that fragment. Since PI inhibits platelet activation by thrombin and ADP it must act via conformational effects and not by blocking the thrombin receptor which lies on the 45 kDa region of glycocalicin. These results support a more complex role for GPIb in platelet activation.

Styles APA, Harvard, Vancouver, ISO, etc.

9

Chumak, N. S., et Y. I. Melnikova. « OBTAINING AND IMMUNOCHEMICAL TESTING OF APOFERRITIN ». Dans SAKHAROV READINGS 2022 : ENVIRONMENTAL PROBLEMS OF THE XXI CENTURY. International Sakharov Environmental Institute of Belarusian State University, 2022. http://dx.doi.org/10.46646/sakh-2022-1-289-293.

Texte intégral

Résumé :

The process of direct binding of monoclonal antibodies to apoferritin immobilized on polystyrene, as well as the method of competitive interaction of monoclonal antibodies with apoferritin in solution, have been experimentally studied. It was found that the immobilization of apoferritin on a polystyrene surface leads to a change in the epitope structure of this protein and to the elimination of reactive epitopes of binding of monoclonal antibodies. The soluble form of apoferritin effectively binds to monoclonal antibodies in a competitive assay, which confirms the conformational nature of the clusters of determinants on the surface of apoferritin.

Styles APA, Harvard, Vancouver, ISO, etc.

10

Berkner, J. A., G. Mitra et J. W. Bloom. « MONOCLONAL ANTIBODY BINDING TO FACTOR VIII:C ». Dans XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644063.

Texte intégral

Résumé :

The interactions of monoclonal antibodies with highly purified Factor VIII:c have been studied utilizing the ELISA technique. ELISA plates were coated with Factor VIII:c, protein A purified monoclonal IgG was then added and bound antibody detected with peroxidase labeled antimouse IgG. A Scatchard-Sips plot approach to data analysis was used to calculate binding constants. The binding constants for four antibodies designated BD10, AD7, C7F7 and 39MH8 were as follows: BD10, KO = 7.1 x 108 M-1, n = 1.1 (moles antibody/moles ligand); AD7, KO = 3.1 x 108 M-1, n = 2.7; C7F7, KO = 3.6 x 1011M-1, n = 0.03; 39MH8, K = 6.0 x 1011 M-1, n = 0.03. The binding constants for C7F7 to the purified carboxy-terminal (residues 1649-2332) 80 kD functional region of the Factor VIII:c molecule were also determined: KO = 1.0 x 1011 M-1, n = 0.55. On the basis of these results the following conclusions can be drawn: 1) the antibodies can be divided into two groups: high affinity (suitable for use in immunopurification), C7F7 and 39MH8; low affinity: BD10 and AD7; 2) the antibodies in the low affinity group have valance values two orders of magnitude higher than the high affinity antibodies, C7F7 and 39MH8. The difference might be explained by the high affinity antibody epitopes on the immobilized Factor VIII:c being less exposed to the solution; 3) C7F7 binding to the 80 kD polypeptide, compared to the whole Factor VIII:c molecule, gave virtually identical Kc values, but dramatically different valance values. This suggests that the C7F7 epitope is more accessible on the 80 kD polypeptide.

Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "Antibodies, Monoclonal"

1

Snyder, Christopher M., et Lawrence J. Wysocki. Dissecting Immunogenicity of Monoclonal Antibodies. Fort Belvoir, VA : Defense Technical Information Center, juin 2002. http://dx.doi.org/10.21236/ada407659.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Snyder, Christopher M., et Lawrence J. Wysocki. Dissecting Immunogenicity of Monoclonal Antibodies. Fort Belvoir, VA : Defense Technical Information Center, juin 2003. http://dx.doi.org/10.21236/ada417364.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Jaszczak, R. J. SPECT assay of radiolabeled monoclonal antibodies. Office of Scientific and Technical Information (OSTI), février 1992. http://dx.doi.org/10.2172/7197646.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Jaszczak, R. J. SPECT assay of radiolabeled monoclonal antibodies. Office of Scientific and Technical Information (OSTI), février 1992. http://dx.doi.org/10.2172/7288347.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Chia, John K. Polymyxin B(PMB)-Specific Monoclonal Antibodies. Fort Belvoir, VA : Defense Technical Information Center, janvier 1991. http://dx.doi.org/10.21236/ada231817.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Ivy, John M. Production of Anti-Ferret IgA Antibodies ; and production of monoclonal antibodies. Fort Belvoir, VA : Defense Technical Information Center, avril 1994. http://dx.doi.org/10.21236/ada279534.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Sato, J. D. Receptor Monoclonal Antibodies that Inhibit Tumor Angiogenesis. Fort Belvoir, VA : Defense Technical Information Center, août 2001. http://dx.doi.org/10.21236/ada398146.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Sato, J. D. Receptor Monoclonal Antibodies that Inhibit Tumor Angiogenesis. Fort Belvoir, VA : Defense Technical Information Center, août 1999. http://dx.doi.org/10.21236/ada383129.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Glassy, Mark C. Neutralizing Monoclonal Antibodies against Biological Toxins. Phase 1. Fort Belvoir, VA : Defense Technical Information Center, août 1993. http://dx.doi.org/10.21236/adb176298.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Jaszczak, Ronald, J. Final Progress Report : SPECT Assay of Radiolabeled Monoclonal Antibodies. Office of Scientific and Technical Information (OSTI), septembre 2004. http://dx.doi.org/10.2172/886018.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!